Veterinary News and Research

RSS

FDA allows marketing of new EarLens Contact Hearing Device

The U.S. Food and Drug Administration today allowed marketing of a new hearing aid that uses a laser diode and direct vibration of the eardrum to amplify sound. The combination of laser light pulses and a custom-fit device component that comes in direct contact with the eardrum is designed to use the patient's own eardrum as a speaker and enables amplification over a wider range of frequencies for some hearing impaired persons.

9 Oct 2015

FDA approves Lonsurf drug for patients with advanced form of colorectal cancer

The U.S. Food and Drug Administration today approved Lonsurf (a pill that combines two drugs, trifluridine and tipiracil) for patients with an advanced form of colorectal cancer who are no longer responding to other therapies.

9 Oct 2015

FDA approves expanded indication for Optune device for brain cancer patients

The U.S. Food and Drug Administration today approved an expanded indication for the Optune device to treat patients with newly-diagnosed glioblastoma multiforme (GBM), an aggressive form of brain cancer.

9 Oct 2015

FDA announces launch of new education campaign to prevent, reduce tobacco use among hip-hop youth

The U.S. Food and Drug Administration today announced the launch of a national public education campaign to prevent and reduce tobacco use among multicultural youth who identify with the hip-hop peer crowd ‒ a group that is often hard to reach and frequently exposed to pro-tobacco images and messages. While multicultural teens identify with more than one group, the FDA is focusing on those in the hip-hop peer crowd because research estimates that they are more likely to use tobacco than other youth.

9 Oct 2015

Xuriden (uridine triacetate) now approved for patients with hereditary orotic aciduria

Today, the U.S. Food and Drug Administration approved Xuriden (uridine triacetate), the first FDA-approved treatment for patients with hereditary orotic aciduria. Hereditary orotic aciduria is a rare metabolic disorder, which has been reported in approximately 20 patients worldwide.

9 Oct 2015

FDA approves Promacta to treat pediatric patients with chronic immune thrombocytopenic purpura

The U.S. Food and Drug Administration today approved Promacta (eltrombopag) to treat low blood platelet count in pediatric patients – ages one year and older – with a rare blood disorder called chronic immune thrombocytopenic purpura (ITP). Promacta can be used in these children when they have not achieved an appropriate response using other ITP medicines or surgery to remove the spleen.

9 Oct 2015

Aristada (aripiprazole lauroxil) extended release injection approved to treat adults with schizophrenia

On October 5, the U.S. Food and Drug Administration approved Aristada (aripiprazole lauroxil) extended release injection to treat adults with schizophrenia. Aristada is administered by a health care professional every four to six weeks using an injection in the arm or buttocks.

9 Oct 2015

Tresiba and Ryzodeg approved to improve blood sugar control in adults with diabetes mellitus

The U.S. Food and Drug Administration today approved Tresiba (insulin degludec injection) and Ryzodeg 70/30 (insulin degludec/insulin aspart injection) to improve blood sugar (glucose) control in adults with diabetes mellitus.

9 Oct 2015

Varubi (rolapitant) approved to prevent delayed phase chemotherapy-induced nausea and vomiting

The U.S. Food and Drug Administration approved Varubi (rolapitant) to prevent delayed phase chemotherapy-induced nausea and vomiting (emesis). Varubi is approved in adults in combination with other drugs (antiemetic agents) that prevent nausea and vomiting associated with initial and repeat courses of vomit-inducing (emetogenic and highly emetogenic) cancer chemotherapy.

9 Oct 2015

Vraylar (cariprazine) capsules now approved by FDA to treat schizophrenia, bipolar disorder in adults

The U.S. Food and Drug Administration today approved Vraylar (cariprazine) capsules to treat schizophrenia and bipolar disorder in adults.

9 Oct 2015

Repatha (evolocumab) injection gets FDA approval for high cholesterol

The U.S. Food and Drug Administration today approved Repatha (evolocumab) injection for some patients who are unable to get their low-density lipoprotein (LDL) cholesterol under control with current treatment options.

9 Oct 2015

FDA grants accelerated approval for Keytruda to treat patients with advanced NSCLC

The U.S. Food and Drug Administration today granted accelerated approval for Keytruda (pembrolizumab) to treat patients with advanced (metastatic) non-small cell lung cancer (NSCLC) whose disease has progressed after other treatments and with tumors that express a protein called PD-L1. Keytruda is approved for use with a companion diagnostic, the PD-L1 IHC 22C3 pharmDx test, the first test designed to detect PD-L1 expression in non-small cell lung tumors.

9 Oct 2015

Phase II psoriasis study shows efficacy of Boehringer Ingelheim's BI 655066 over ustekinumab

New results from a Phase II head-to-head psoriasis study showed superior efficacy of Boehringer Ingelheim's investigational biologic compound BI 655066, over ustekinumab. After nine months, 69 percent of patients with moderate-to-severe plaque psoriasis maintained clear or almost clear skin (PASI 90) with BI 655066 in the higher dose group compared to 30 percent of patients on ustekinumab.

8 Oct 2015

OSU researchers develop new approach to treat eczema

Pharmaceutical researchers at Oregon State University have developed a new approach to treat eczema and other inflammatory skin disorders that would use individual tests and advanced science to create personalized treatments based on each person's lipid deficiencies.

1 Oct 2015

Sikka Software's cloud-based practice optimization platform transforms retail healthcare industry

Retail healthcare is a $220 billion industry, representing over 2.1 million providers and 400 million patients in just 5 markets of US, UK, Canada, Australia and New Zealand. Sikka Software, a leading innovator in business intelligence software for the retail healthcare industry, today announced its cloud-based practice optimization platform is helping practices increase revenue and profitability by leveraging key information from existing customer data.

30 Sep 2015

Philip Chapper & Co to showcase new partner products at Europe’s largest pharmaceutical trade fair

Philip Chapper & Company Ltd, a UK company with over 40 years’ experience within medical supplies, is to showcase innovative products from new suppliers at the industry’s largest European trade fair.

28 Sep 2015

Inflammatory response could be key link between dietary fats and obesity-related diseases

An enhanced inflammatory response could be the key link between high saturated fat intake - a recognized risk factor for obesity-related disorders - and the development of diseases like type 2 diabetes and atherosclerosis.

26 Sep 2015

Protein-coding gene identified as tumor suppressor for acute myeloid leukemia

A protein-coding gene called hnRNP K has been identified as a tumor suppressor for acute myeloid leukemia (AML), a finding that could be important for investigating how best to target treatment of a blood cancer striking mostly older individuals.

24 Sep 2015

People who visit South London parks at risk of coming into contact with ticks linked to Lyme disease

Visitors to 2 popular parks in South London are at risk of coming into contact with ticks that can transmit Lyme disease to humans, according to a new study in Medical and Veterinary Entomology.

24 Sep 2015

Female mice exposed to endocrine disruptors may show decreased metabolism, physical activity in offspring

Endocrine disruptors are contaminants that interfere with endocrine or hormone systems and can cause tumors, birth defects and developmental disorders in mammals. Often, these contaminants are used in a variety of consumer products, such as water bottles, dental composites and resins used to line metal food and beverage containers.

22 Sep 2015

Veterinary News and Research

FDA allows marketing of new EarLens Contact Hearing Device

FDA approves Lonsurf drug for patients with advanced form of colorectal cancer

FDA approves expanded indication for Optune device for brain cancer patients

FDA announces launch of new education campaign to prevent, reduce tobacco use among hip-hop youth

Xuriden (uridine triacetate) now approved for patients with hereditary orotic aciduria

FDA approves Promacta to treat pediatric patients with chronic immune thrombocytopenic purpura

Aristada (aripiprazole lauroxil) extended release injection approved to treat adults with schizophrenia

Tresiba and Ryzodeg approved to improve blood sugar control in adults with diabetes mellitus

Varubi (rolapitant) approved to prevent delayed phase chemotherapy-induced nausea and vomiting

Vraylar (cariprazine) capsules now approved by FDA to treat schizophrenia, bipolar disorder in adults

Repatha (evolocumab) injection gets FDA approval for high cholesterol

FDA grants accelerated approval for Keytruda to treat patients with advanced NSCLC

Phase II psoriasis study shows efficacy of Boehringer Ingelheim's BI 655066 over ustekinumab

OSU researchers develop new approach to treat eczema

Sikka Software's cloud-based practice optimization platform transforms retail healthcare industry

Philip Chapper & Co to showcase new partner products at Europe’s largest pharmaceutical trade fair

Inflammatory response could be key link between dietary fats and obesity-related diseases

Protein-coding gene identified as tumor suppressor for acute myeloid leukemia

People who visit South London parks at risk of coming into contact with ticks linked to Lyme disease

Female mice exposed to endocrine disruptors may show decreased metabolism, physical activity in offspring

Sensing a Healthier Future

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Latest News